Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

Related Keywords

United States ,Americans ,American ,Dana Farber Kennethc Anderson ,Nikhil Munshi ,Emily Henderson ,Paulg Richardson ,National Cancer Institute ,Rj Corman Multiple Myeloma Research Fund ,Jerome Lipper Multiple Myeloma Center ,Marrow Transplant Clinical Trials Network ,Millennium Takeda Pharmaceutical Biotech Company ,Jerome Lipper Multiple Myeloma Center At Dana Farber ,Lebow Institute For Myeloma Therapeutics ,Dana Farber Cancer Institute ,Blood Institute ,National Heart ,Annual Meeting ,American Society ,Clinical Oncology ,New England Journal ,African American ,African Americans ,Lebow Institute ,Myeloma Therapeutics ,Correlative Science ,Multiple Myeloma Research Fund ,Cell ,Multiple Myeloma ,Myeloma ,Transplant ,Antibodies ,Flood ,Dancer ,Chemotherapy ,Children ,Clinical Trial ,Drugs ,Hospital ,Leukemia ,Medicine ,Ncology ,Research ,Stem Cells ,